Abstract:Key PointsAcross evolutionary time, inflammatory responses and depressive symptoms were part of an integrated adaptive response to pathogens that facilitated fighting infection, healing wounds and avoiding subsequent pathogen exposure in the pathogen-rich environments in which humans evolved. In the more sanitary environments of the modern world, the relationship between inflammatory pathways and the brain may drive depression and contribute to non-response to antidepressant medication.Increased levels of inflammatory cytokines and induction of their signalling pathways as well as activation of different immune cell subsets has been detected in the brain and peripheral blood of a subgroup of patients with depression. C-reactive protein (CRP), tumour necrosis factor, interleukin-1β (IL-1β) and IL-6 appear to be the most reliably elevated inflammatory markers in the peripheral blood of subjects with depression.Activation of the inflammasome by stress-induced, non-pathogenic stimuli, including damage-associated molecular patterns as well as microbial-associated molecular patterns elaborated from the gut microbiome, may drive peripheral inflammatory responses, which are then transmitted to the brain by trafficking of activated monocytes.Inflammation impacts several neurotransmitter systems in the brain, including serotonin, dopamine and glutamate pathways, as well as the kynurenine pathway, which generates the neurotoxic metabolite quinolinic acid. Neuroimaging studies have demonstrated that disruption of neurotransmitter pathways is associated with inflammation-induced alterations in brain circuits that mediate motivation and motor activity as well as anxiety, arousal and alarm.Activation of effector T cells during stress can prevent the development of depressive- and anxiety-like behaviour in mice. These effects may be mediated by the trafficking of effector T cells to the meningeal space where they produce IL-4, which supports anti-inflammatory responses while also stimulating the production of growth factors in the brain that support neural plasticity and resilience.Studies in depression suggest that inflammatory biomarkers, such as CRP, can be used to enrich samples for anti-inflammatory clinical trials for depression that target inflammation-related symptoms such as anhedonia and anxiety, thereby supporting intelligent trial design. Though still in development, imaging of neuroinflammation will help establish a 'target' in the brain to further facilitate the testing of anti-inflammatory therapies for depression.

NLRP3 inflammatory pathway. Can we unlock depression?

The NLRP3 inflammasome in depression: Potential mechanisms and therapies

Microglial NLRP3 inflammasome-mediated neuroinflammation and therapeutic strategies in depression

NLRP3 Inflammasome, NEK7 and Major Depressive Disorder

P2RY12 Increased Neuroinflammation to Accelerate Depression-like Behaviors by the NLPR3 Inflammasome

Stress-Induced Depressive Behaviors Require a Functional NLRP3 Inflammasome.

Nlrp3 Inflammasome Mediates Chronic Mild Stress-Induced Depression in Mice Via Neuroinflammation

Brain-derived neurotrophic factor and inflammation in depression: Pathogenic partners in crime?

Research progress on the relationship between NLRP3 inflammatory body and depression

The Significance of NLRP Inflammasome in Neuropsychiatric Disorders

Targeting NLRP3 Inflammasome in Translational Treatment of Nervous System Diseases: An Update

Neuroinflammation and depression: A review

Possible role of the NLRP3 inflammasome and the gut–brain axis in multiple sclerosis‐related depression

Lysosomal dysfunction is associated with NLRP3 inflammasome activation in chronic unpredictable mild stress-induced depressive mice

P2X7 receptors from the perspective of NLRP3 inflammasome pathway in depression: Potential role of cannabidiol

The Microbiota‐Inflammasome Hypothesis of Major Depression

P2X7 receptor mediates NLRP3 inflammasome activation in depression and diabetes

Involvement of inflammasome activation in lipopolysaccharide-induced mice depressive-like behaviors.

The Cytokine Hypothesis of Depression: Inflammation, Oxidative & Nitrosative Stress (IO&NS) and Leaky Gut As New Targets for Adjunctive Treatments in Depression.

The role of inflammation in depression: from evolutionary imperative to modern treatment target

Autophagy dysfunction contributes to NLRP1 inflammasome-linked depressive-like behaviors in mice